NASDAQ:BSX 30 December 2025 - 10 February 2026

Boston Scientific shares edged down 0.2% to $77.49 in late-morning trading Friday, following a wild two-day rollercoaster that has investors scrambling for insight into the medical-device company’s growth drivers.

Shares of Boston Scientific Corp ended Friday up 1.3% at $92.51. Late in the session, Fitch Ratings revised the medical-device maker’s outlook to Positive, while keeping its A- and F1 issuer ratings unchanged. Fitch noted this could pave the way for an upgrade to “A” once the company’s financials stabilize following its planned Penumbra acquisition. The agency also highlighted leverage peaking near 3.3 times by the end of 2026 based on its projections.